AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35167031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole 300 mg twice on day 1, then 300 mg once daily on days 2-10, and either 300 mg once daily or oral suspension 200 mg 3 times daily for up to 18 days for a maximum of 28 days.
Number of subjects: 70
Study 35167031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole (intensive PK group)
Number of subjects: 70
Study 35167031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole (sparse PK group)
Number of subjects: 70
Study 35167051 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day) as an add-on to metformin for 18 months
Number of subjects: 135
Study 35167136 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced peri-operative care pathway (high-risk surgical bundle)
Number of subjects: 1189
Study 35167136 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1189
Study 35167187 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg twice daily
Number of subjects: 331
Study 35167187 — intervention group
Group type: COMPARATOR
Intervention: Prednisone on a tapering schedule
Number of subjects: 331
Study 35167312 — intervention group
Group type: EXPERIMENTAL
Intervention: High childhood trauma (Early Trauma Inventory Self Report-Short Form ≥10)
Number of subjects: 320
Study 35167312 — intervention group
Group type: COMPARATOR
Intervention: Low childhood trauma (Early Trauma Inventory Self Report-Short Form <10)
Number of subjects: 320
Study 35167329 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib 600 mg twice a day
Number of subjects: 25
Study 35167586 — intervention group
Group type: EXPERIMENTAL
Intervention: PWUD with TB disease who smoke illicit drugs
Number of subjects: 750
Study 35167586 — intervention group
Group type: EXPERIMENTAL
Intervention: PWUD with microbiologic evidence of TB disease
Number of subjects: 750
Study 35167586 — intervention group
Group type: EXPERIMENTAL
Intervention: PWUD
Number of subjects: 750
Study 35167586 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TB cases among PWUD
Number of subjects: 750
Study 35167655 — intervention group
Group type: EXPERIMENTAL
Intervention: tisagenlecleucel
Number of subjects: 12
Study 35167866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal signature Sa∪Sc
Number of subjects: 1043
Study 35167866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal signature Sa
Number of subjects: 1043
Study 35167866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal signature Sc
Number of subjects: 1043
Study 35167907 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE) in children treated with anthracyclines
Number of subjects: 196
Study 35167907 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 196
Study 35167972 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free remission at 5 years
Number of subjects: 412
Study 35167972 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom duration
Number of subjects: 412
Study 35167972 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ-AS score
Number of subjects: 412
Study 35167972 — intervention group
Group type: EXPERIMENTAL
Intervention: ASDAS score
Number of subjects: 412
Study 35167972 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAS-NSAID score
Number of subjects: 412
Study 35167972 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF use
Number of subjects: 412
Study 35167984 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-LSI[4m] >59%
Number of subjects: 113
Study 35167984 — intervention group
Group type: EXPERIMENTAL
Intervention: H-LSI[4m] >72%
Number of subjects: 113
Study 35168241 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 62
Study 35168241 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomic myomectomy
Number of subjects: 62
Study 35168380 — intervention group
Group type: EXPERIMENTAL
Intervention: Social resources provided during discharge support
Number of subjects: 0
Study 35168380 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35168547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg on days -14 and -7, followed by gemcitabine/cisplatin every 3 weeks, and rituximab every 6 months thereafter (Protocol 1)
Number of subjects: 10
Study 35168547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 concomitantly with gemcitabine/cisplatin (Protocol 2)
Number of subjects: 10
Study 35168565 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled asthma contacts in primary health care (PHC)
Number of subjects: 203
Study 35168565 — intervention group
Group type: COMPARATOR
Intervention: Scheduled asthma contacts in secondary care
Number of subjects: 203
Study 35168565 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption
Number of subjects: 203
Study 35168605 — intervention group
Group type: EXPERIMENTAL
Intervention: Asprosin treatment in HUVECs
Number of subjects: 114
Study 35168605 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating asprosin levels in DM + PAD group
Number of subjects: 114
Study 35168605 — intervention group
Group type: EXPERIMENTAL
Intervention: Asprosin as a diagnostic marker
Number of subjects: 114
Study 35168605 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 114
Study 35168605 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics data
Number of subjects: 114
Study 35168605 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-β signaling pathway
Number of subjects: 114
Study 35168661 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI) integrated into youth entrepreneurship programs (ENTR)
Number of subjects: 0
Study 35168661 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative team approach (CTA)
Number of subjects: 0
Study 35168661 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth entrepreneurship and livelihood programs
Number of subjects: 0
Study 35168844 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin (EV)
Number of subjects: 125
Study 35168985 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial sensor technology for sensorimotor control assessment
Number of subjects: 104
Study 35168985 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity levels
Number of subjects: 104
Study 35168985 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 104
Study 35168985 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms related to central sensitisation
Number of subjects: 104
Study 35168985 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability of the inertial measurement unit sensor technology
Number of subjects: 104
Study 35168986 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g five-point oral glucose tolerance test (OGTT) during and after pregnancy
Number of subjects: 800
Study 35168989 — intervention group
Group type: EXPERIMENTAL
Intervention: ICTAL Registry observational methods
Number of subjects: 0
Study 35168989 — intervention group
Group type: EXPERIMENTAL
Intervention: Core data set from ICTAL Registry
Number of subjects: 0
Study 35169140 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated with prednisone and/or antibiotics in the outpatient setting
Number of subjects: 60
Study 35169140 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated in an urgent care or ED setting
Number of subjects: 60
Study 35169140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized
Number of subjects: 60
Study 35169140 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 60
Study 35169170 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) measured on admission
Number of subjects: 540
Study 35169170 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological data recording and HRV parameters (LF/HF and Shannon entropy)
Number of subjects: 540
Study 35169170 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning using neural network (kNN)
Number of subjects: 540
Study 35169170 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV measured on admission
Number of subjects: 540
Study 35169806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91
Study 35169806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal followed by intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91
Study 35169968 — intervention group
Group type: EXPERIMENTAL
Intervention: Masimo O3™ regional cerebral oxygen saturation (rSO2) monitoring
Number of subjects: 0
Study 35170026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs (heart rate, respiratory rate, peripheral oxygen saturation, blood pressure) for up to 96 hours
Number of subjects: 500
Study 35170026 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs
Number of subjects: 500
Study 35170053 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) levels in human milk
Number of subjects: 100
Study 35170053 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for other fatty acids and maternal characteristics
Number of subjects: 100
Study 35170082 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide plus prednisone, etoposide, and thalidomide (CPET regimen) for a total of eight cycles
Number of subjects: 71
Study 35170082 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide plus prednisone, etoposide, and thalidomide (CPET regimen)
Number of subjects: 71
Study 35170571 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinjury ADHD (PADHD)
Number of subjects: 284
Study 35170571 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary ADHD (SADHD)
Number of subjects: 284
Study 35170571 — intervention group
Group type: COMPARATOR
Intervention: No ADHD
Number of subjects: 284
Study 35170751 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPi) with chemotherapy
Number of subjects: 6109
Study 35170751 — intervention group
Group type: COMPARATOR
Intervention: PARPi monotherapy
Number of subjects: 6109
Study 35170751 — intervention group
Group type: COMPARATOR
Intervention: PARPi maintenance therapy
Number of subjects: 6109
Study 35170772 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy (40%), double pass helium plasma dermal resurfacing (HPDR)
Number of subjects: 55
Study 35170772 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy (40%), double pass HPDR
Number of subjects: 55
Study 35171146 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoura Vision using the Wavelight EX500 excimer laser
Number of subjects: 65
Study 35171213 — intervention group
Group type: EXPERIMENTAL
Intervention: LiveOne device (cuffless wristband)
Number of subjects: 34
Study 35171350 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib alone
Number of subjects: 29
Study 35171350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib and panitumumab combination therapy
Number of subjects: 29
Study 35171362 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for substance use risk reduction
Number of subjects: 306
Study 35171362 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for sexual risk reduction
Number of subjects: 306
Study 35171362 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for personal or emotional problems
Number of subjects: 306
Study 35171362 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for tangible aid or service
Number of subjects: 306
Study 35171658 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib 30 mg by mouth once weekly
Number of subjects: 38
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors (duration: 12 months)
Number of subjects: 3896
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent discontinuation of P2Y12 inhibitors
Number of subjects: 3896
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-driven non-adherence
Number of subjects: 3896
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk profile change
Number of subjects: 3896
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of non-adherence
Number of subjects: 3896
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: POCE (patient-oriented composite endpoint)
Number of subjects: 3896
Study 35171913 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors for POCE
Number of subjects: 3896
Study 35171989 — intervention group
Group type: EXPERIMENTAL
Intervention: New small non-cortical infarcts (SNCIs) and large non-cortical or cortical infarcts (LNCCIs)
Number of subjects: 1227
Study 35171989 — intervention group
Group type: COMPARATOR
Intervention: No new brain infarcts
Number of subjects: 1227
Study 35172272 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + fulvestrant
Number of subjects: 124
Study 35172286 — intervention group
Group type: COMPARATOR
Intervention: 110-projection adaptive-acquisition MCFDK-reconstruction
Number of subjects: 20
Study 35172286 — intervention group
Group type: COMPARATOR
Intervention: 110-projection adaptive-acquisition SMEIR-reconstruction
Number of subjects: 20
Study 35172286 — intervention group
Group type: COMPARATOR
Intervention: 110-projection adaptive-acquisition
Number of subjects: 20
Study 35172286 — intervention group
Group type: COMPARATOR
Intervention: All adaptive-acquisition reconstruction methods
Number of subjects: 20
Study 35172518 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 35172518 — intervention group
Group type: EXPERIMENTAL
Intervention: AR expression threshold ≥ 10% nuclear expression
Number of subjects: 0
Study 35172719 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise as a treatment for chronic low back pain
Number of subjects: 10
Study 35172719 — intervention group
Group type: COMPARATOR
Intervention: Biomedical model of treatment
Number of subjects: 10
Study 35172719 — intervention group
Group type: COMPARATOR
Intervention: Misbeliefs about chronic low back pain
Number of subjects: 10
Study 35172722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hemodynamics (including diastolic pressure gradient (DPG) and mixed venous oxygen saturation (SvO2))
Number of subjects: 276
Study 35172722 — intervention group
Group type: COMPARATOR
Intervention: Seattle heart failure model (SHFM)
Number of subjects: 276
Study 35172722 — intervention group
Group type: COMPARATOR
Intervention: Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) scores
Number of subjects: 276
Study 35172756 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal pain consultation
Number of subjects: 100
Study 35173290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment at diagnosis
Number of subjects: 824
Study 35173720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined kidney and hematopoietic stem cell transplantation with anti-thymocyte globulin induction, 10x 1.2 Gy total lymphoid irradiation, CD34+ cells transfusion, and donor T cells.
Number of subjects: 3
Study 35173817 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st line 1G/2G EGFR-TKIs (most frequently afatinib, 45%)
Number of subjects: 896
Study 35173817 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st line 1G/2G EGFR-TKIs
Number of subjects: 896
Study 35174001 — intervention group
Group type: EXPERIMENTAL
Intervention: BP2.0 online mindfulness-based intervention
Number of subjects: 69
Study 35174078 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR) after induction chemotherapy with XELOX or mFOLFOX6
Number of subjects: 140
Study 35174078 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-alone (no PTR)
Number of subjects: 140
Study 35174078 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR)
Number of subjects: 140
Study 35174078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor regression grade (TRG) score of 2
Number of subjects: 140
Study 35174220 — intervention group
Group type: EXPERIMENTAL
Intervention: Second peak of high-sensitivity cardiac troponin T (hs-cTnT) after myocardial infarction
Number of subjects: 192
Study 35174220 — intervention group
Group type: COMPARATOR
Intervention: No second peak of high-sensitivity cardiac troponin T (hs-cTnT) after myocardial infarction
Number of subjects: 192
Study 35174332 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Driving Simulator (VRDS)
Number of subjects: 11
Study 35174366 — intervention group
Group type: EXPERIMENTAL
Intervention: A1HPV6 risk calculator
Number of subjects: 127
Study 35174366 — intervention group
Group type: EXPERIMENTAL
Intervention: A1HPV6 components
Number of subjects: 127
Study 35174462 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared epitope positive (SE+) patients
Number of subjects: 926
Study 35174462 — intervention group
Group type: COMPARATOR
Intervention: Shared epitope negative (SE-) patients
Number of subjects: 926
Study 35174470 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 735
Study 35174470 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 735
Study 35174470 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week and 12-week glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 735
Study 35174749 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) techniques for identifying clinical phenotypes of T2D
Number of subjects: 1030
Study 35174756 — intervention group
Group type: EXPERIMENTAL
Intervention: BETTER intervention
Number of subjects: 15
Study 35174801 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep OCT atrophy detection (deep learning-based algorithm)
Number of subjects: 127
Study 35174809 — intervention group
Group type: EXPERIMENTAL
Intervention: DPED collapse
Number of subjects: 25
Study 35174809 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovascular age-related macular degeneration
Number of subjects: 25
Study 35174809 — intervention group
Group type: EXPERIMENTAL
Intervention: DPED persistence
Number of subjects: 25
Study 35174809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean time to DPED collapse
Number of subjects: 25
Study 35174809 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hyperreflective foci
Number of subjects: 25
Study 35175067 — intervention group
Group type: EXPERIMENTAL
Intervention: TUD subjects during LATER condition
Number of subjects: 78
Study 35175067 — intervention group
Group type: EXPERIMENTAL
Intervention: TUD subjects
Number of subjects: 78
Study 35175067 — intervention group
Group type: COMPARATOR
Intervention: NS subjects
Number of subjects: 78
Study 35175200 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Incredible Years Basic Parent Training Program (IY)
Number of subjects: 180
Study 35175200 — intervention group
Group type: COMPARATOR
Intervention: American Academy of Pediatrics' Bright Future handouts (waitlist control)
Number of subjects: 180
Study 35175229 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide injection at 2.4 mg once weekly
Number of subjects: 0
Study 35175229 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program (reduced calorie diet and increased physical activity)
Number of subjects: 0
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month outcomes including extended Glasgow Outcome Scale ≥ 6
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month higher mean SF-12 physical component summary
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month higher mean SF-12 mental component summary
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month higher EQ5D health index
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower physical requirements in pre-injury job nature
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational levels
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-work-related injuries
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter hospital length of stay
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: No requirement for surgery
Number of subjects: 1115
Study 35175362 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who could be discharged home
Number of subjects: 1115
Study 35175381 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimodal ultrasound ML algorithms
Number of subjects: 1288
Study 35175381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal ultrasound ML algorithms
Number of subjects: 1288
Study 35175381 — intervention group
Group type: COMPARATOR
Intervention: Routine breast cancer diagnosis
Number of subjects: 1288
Study 35175691 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim and PCP
Number of subjects: 33
Study 35175691 — intervention group
Group type: COMPARATOR
Intervention: PCP alone
Number of subjects: 33
Study 35176173 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated absence seizure detection using a wearable EEG device
Number of subjects: 102
Study 35176173 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated behavioral testing triggered by automated seizure detection
Number of subjects: 102
Study 35176401 — intervention group
Group type: EXPERIMENTAL
Intervention: D124N variant of GCK
Number of subjects: 0
Study 35176457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib 1-20 mg once daily intermittently (2 weeks on/1 week off; n = 70) or continuously (n = 58)
Number of subjects: 128
Study 35176457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 128
Study 35176488 — intervention group
Group type: EXPERIMENTAL
Intervention: F1CDx (next-generation sequencing-based test)
Number of subjects: 6802
Study 35176488 — intervention group
Group type: EXPERIMENTAL
Intervention: F1CDx
Number of subjects: 6802
Study 35176488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 6802
Study 35176527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative PCO
Number of subjects: 90
Study 35176527 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 90